Dated: January 5, 2021.

Jennifer M. Guimond,
Project Clearance Liaison, Eunice Kennedy
Shriver National Institute of Child Health and
Human Development, National Institutes of
Health.

[FR Doc. 2021–00636 Filed 1–13–21; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.

The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Institute
of Allergy and Infectious Diseases Special
Emphasis Panel; A Solicitation of the
National Institutes of Health (NIH) and the
Centers for Disease Control and Prevention
(CDC) for Small Business Innovation
Research (SBIR) Contract Proposals (N01).

Topic 100.

Date: February 2, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.

Place: National Institute of Allergy and
Infectious Diseases, National Institutes
of Health, 5601 Fishers Lane, Room
3G62A, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Lynn Rust, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G62A, Rockville, MD
20892, (301) 594–9460, lrust@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)

Dated: January 8, 2021.

Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2021–00575 Filed 1–13–21; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;
Notice of Closed Meeting

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.

The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploring Epigenomic or Non-Coding RNA
Regulation in the Development,
Maintenance, or Treatment of Chronic Pain
(R61/R33 Clinical Trial Optional).

Date: February 22, 2021.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health
National Institute on Drug Abuse 301 North
Stonestreet Avenue Bethesda, MD 20892
(Virtual Meeting).

Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)

Dated: January 8, 2021.

Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2021–00575 Filed 1–13–21; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research;
Notice of Closed Meetings

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.

The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Institute of
Nursing Research Special Emphasis Panel;
Modular Budget Research Project Grant for
NIH Nurse Scientist Scholars.

Date: February 5, 2021.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.

Place: National Institute of Nursing
Research, National Institutes of Health, 6701
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ming Yan, MD, Ph.D., Scientific Review Officer, Immunology (IMM), DPPS, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, RM 4205, Bethesda, MD 20892, (301) 594–0343, yanning@mail.nih.gov.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; Fellowship and Career Development.

Date: February 19, 2021.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Ming Yan, MD, Ph.D., Scientific Review Officer, Immunology (IMM), DPPS, Center for Scientific Review, National Institute of Nursing Research, National Institutes of Health, 6701 Rockledge Drive, RM 4205 Bethesda, MD 20892, (301) 594–0343, yanning@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Basic Science Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 8, 2021.

Tyeshia Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[F] [R Doc. 2021–00653 Filed 1–13–21; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

Date: April 31–May 5, 2021.

Time: 9:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lorna W. Role, Ph.D., Scientific Director, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, 35A Convent Drive, MSC 3716, Bethesda, MD 20892, lorna.role@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Basic Science Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 8, 2021.

Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.

[F] [R Doc. 2021–00653 Filed 1–13–21; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD33-Specific Chimeric Antigen Receptor (CAR) Therapies for CD33-Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio ("Senti"), located in South San Francisco, CA.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before January 29, 2021 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jim Knabb, Senior Technology Transfer Manager, NCI Technology Transfer Center at Email: jim.knabb@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

E–097–2018–0: Anti-CD33 Chimeric Antigen Receptors for Treatment of Human Acute Myeloid Leukemia


10. India Application No: 202047039152, filed September 10, 2020 (E–097–2018–0–IN–10)


The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

An exclusive license to:

1. The development of a CD33-specific logic-gated CAR-based...